Dr. Kimmie Ng, MD

Dr. Ng practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Dr. Ng's NPI, 1740263045, was assigned on November 22, 2005. Dr. Ng graduated from Perelman School of Med at the University of Pennsylvania in 2001. Dr. Ng holds Massachusetts license 223906.

Dr. Ng's primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Dr. Ng's primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Ng is also affiliated with Brigham and Women's Hospital. The medical group on file is Binney Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ng practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Ng's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Ng is licensed in Massachusetts.

CMS data shows 78 Medicare services from Dr. Ng across 2 procedure codes in 2024, all of them office visits, for 40 Medicare patients. Medicare paid $7,527 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 40 Medicare patients who saw Dr. Ng in 2024. The largest group is 65 to 74, with 25 patients. 75% of them have cancer, and 58% have high cholesterol. Their average risk score is 2.21, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ng's median patient age at 63, with 50% women.

In 2024, Dr. Ng wrote 35 Medicare Part D claims for 11 patients. 66% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $96 in total drug cost. In 2017, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Ng for performance year 2024, reported as part of a group. Dr. Ng accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ng as offering telehealth.

Dmand AI links 214 papers to Dr. Ng, published from 2009 to 2025. 2020 was the busiest year, with 20. The most frequent topics are Colorectal Neoplasms, Pancreatic Neoplasms and Vitamin D. Dr. Ng has published most often in Cancer Epidemiol Biomarkers Prev. Dr. Ng's most frequent co-authors are Charles Stewart Fuchs, MD, MPH, Marios Giannakis, MD and Robert James Mayer, MD.

Dmand AI links Dr. Ng to 9 clinical trials, 5 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Rectal Diseases, Colorectal Neoplasms and Rectal Neoplasms. Academic and Community Cancer Research United sponsors the most, 4.

CMS Open Payments shows 62 general payments to Dr. Ng from 11 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 60% of the total. GlaxoSmithKline, LLC. paid the most, $25,069. It also lists 6 research payments totaling $7,430 from 2022 to 2025.

Dr. Ng graduated from Perelman School of Med at the University of Pennsylvania in 2001.